AdvaMed Applauds Congressional Diabetes Caucus on Medicare Bidding Concerns
AdvaMed, the leading trade association for medical technology innovators, has expressed strong support for concerns raised by a bipartisan group of U.S. lawmakers regarding Medicare’s proposed bidding rules. The legislators, including Senators Susan Collins and Jeanne Shaheen, and Representatives Diana DeGette and Gus Bilirakis, co-chairs of the Senate and House Diabetes Caucuses, sent a letter to the Centers for Medicare and Medicaid Services (CMS) urging caution.
Concerns Over Continuous Glucose Monitors
The lawmakers warned that the CMS proposal could restrict access to essential diabetes management devices, particularly continuous glucose monitors (CGMs) and durable insulin pumps. AdvaMed President and CEO Scott Whitaker emphasized the importance of these technologies in helping millions of Americans manage diabetes effectively.
“Diabetes is a serious condition that requires effective management,” Whitaker stated. “The devices in question not only help prevent severe complications but also reduce healthcare costs associated with hospital visits.”
Flaws in Proposed Bidding Rules
AdvaMed’s formal comments on the CMS’s proposed rules highlighted several significant issues. The organization called for the proposal to be revised due to:
- Potential risks to patient safety.
- Limited product choices for beneficiaries.
- Possibility of increased healthcare costs.
Whitaker noted that adequate access to diabetes management technologies is already insufficient for many patients. He urged policymakers to ensure that any new regulations enhance, rather than hinder, access to critical medical devices.
Recognition of Diabetes Awareness Month
As November approaches, AdvaMed plans to showcase advancements in diabetes management technology. Their initiatives will be featured on social media platforms, highlighting the importance of these devices for those affected by diabetes.
AdvaMed advocates for the need for Medicare beneficiaries to have access to a comprehensive range of safe and effective diabetes treatment options recommended by healthcare professionals. Proper support for diabetes medtech is essential for improving patient outcomes and managing healthcare costs effectively.
